CBD shows therapeutic potential across a wide range of neuropsychiatric disorders with few side effects
A review found CBD has shown benefit for autism, anxiety, psychosis, neuropathic pain, epilepsy, and several neurodegenerative diseases, with common side effects limited to diarrhea and somnolence and low abuse potential.
Quick Facts
What This Study Found
CBD has demonstrated therapeutic benefit across multiple neuropsychiatric conditions including autism spectrum disorder, anxiety, psychosis, neuropathic pain, cancer pain, migraine, MS, Alzheimer disease, Parkinson disease, Huntington disease, hypoxic-ischemic injury, and epilepsy. CBD is generally well tolerated with low abuse potential. THC limitations may restrict some clinical applications.
Key Numbers
CBD shows benefit across 12+ neuropsychiatric conditions listed. Most common adverse events: diarrhea and somnolence. Low abuse potential demonstrated. Over 100 naturally occurring cannabinoid chemicals in cannabis.
How They Did This
Updated narrative review of CBD and cannabinoid therapeutic potential, with emphasis on the distinction between psychotropic THC and non-psychotropic CBD effects across neuropsychiatric conditions.
Why This Research Matters
The breadth of conditions where CBD shows promise, combined with its favorable safety profile, makes it one of the most versatile therapeutic candidates currently being investigated across neurology and psychiatry.
The Bigger Picture
CBD sits at the intersection of neurology, psychiatry, and pain medicine. If even a fraction of its therapeutic potential is confirmed in rigorous trials, it could reshape treatment approaches across multiple medical specialties.
What This Study Doesn't Tell Us
Narrative review format without systematic methodology. Many of the cited benefits are based on preliminary evidence. The review covers conditions at very different evidence levels without always distinguishing them.
Questions This Raises
- ?Which of these many potential indications will hold up in rigorous RCTs?
- ?What is the optimal dose for each condition?
- ?Can CBD be standardized and dosed reliably enough for mainstream clinical use?
Trust & Context
- Key Stat:
- Low abuse potential
- Evidence Grade:
- Rated moderate because the review covers a wide range of evidence, though the depth for individual conditions varies significantly.
- Study Age:
- Published in 2019.
- Original Title:
- Cannabis and Neuropsychiatric Disorders: An Updated Review.
- Published In:
- Acta neurologica Taiwanica, 28(2), 27-39 (2019)
- Authors:
- Chayasirisobhon, Sirichai
- Database ID:
- RTHC-01979
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What conditions might CBD help?
The review lists potential benefits for autism, anxiety, psychosis, neuropathic and cancer pain, migraine, MS, several neurodegenerative diseases, and epilepsy. Evidence strength varies significantly by condition.
Is CBD safe?
CBD is generally well tolerated with main side effects of diarrhea and somnolence. It has demonstrated low abuse potential, distinguishing it from THC.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01979APA
Chayasirisobhon, Sirichai. (2019). Cannabis and Neuropsychiatric Disorders: An Updated Review.. Acta neurologica Taiwanica, 28(2), 27-39.
MLA
Chayasirisobhon, Sirichai. "Cannabis and Neuropsychiatric Disorders: An Updated Review.." Acta neurologica Taiwanica, 2019.
RethinkTHC
RethinkTHC Research Database. "Cannabis and Neuropsychiatric Disorders: An Updated Review." RTHC-01979. Retrieved from https://rethinkthc.com/research/chayasirisobhon-2019-cannabis-and-neuropsychiatric-disorders
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.